X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (14078) 14078
Book Review (3206) 3206
Publication (1395) 1395
Conference Proceeding (47) 47
Book Chapter (44) 44
Magazine Article (9) 9
Dissertation (8) 8
Web Resource (4) 4
Book / eBook (2) 2
Data Set (2) 2
Presentation (2) 2
Government Document (1) 1
Reference (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (11971) 11971
humans (11920) 11920
bevacizumab (11804) 11804
female (6829) 6829
oncology (5847) 5847
male (5666) 5666
middle aged (4957) 4957
angiogenesis inhibitors - therapeutic use (4721) 4721
aged (4616) 4616
antineoplastic combined chemotherapy protocols - therapeutic use (3403) 3403
cancer (3377) 3377
chemotherapy (3365) 3365
adult (3310) 3310
treatment outcome (3288) 3288
antibodies, monoclonal, humanized (3003) 3003
ophthalmology (2975) 2975
vascular endothelial growth factor a - antagonists & inhibitors (2864) 2864
endothelial growth-factor (2726) 2726
vascular endothelial growth factor (2544) 2544
antibodies, monoclonal - therapeutic use (2419) 2419
angiogenesis (2312) 2312
care and treatment (2228) 2228
aged, 80 and over (2068) 2068
antibodies, monoclonal, humanized - therapeutic use (2005) 2005
antineoplastic agents - therapeutic use (1793) 1793
retrospective studies (1768) 1768
therapy (1733) 1733
animals (1707) 1707
ranibizumab (1640) 1640
metastasis (1587) 1587
medicine & public health (1566) 1566
colorectal neoplasms - drug therapy (1539) 1539
intravitreal injections (1522) 1522
research (1436) 1436
angiogenesis inhibitors - administration & dosage (1405) 1405
colorectal cancer (1404) 1404
disease-free survival (1390) 1390
antibodies, monoclonal, humanized - administration & dosage (1388) 1388
macular degeneration (1376) 1376
pharmacology & pharmacy (1303) 1303
drug therapy (1282) 1282
survival (1255) 1255
antibodies, monoclonal - administration & dosage (1239) 1239
prognosis (1196) 1196
bevacizumab - therapeutic use (1194) 1194
trial (1192) 1192
vegf (1187) 1187
analysis (1182) 1182
angiogenesis inhibitors (1154) 1154
colorectal neoplasms - pathology (1143) 1143
angiogenesis inhibitors - adverse effects (1112) 1112
tomography, optical coherence (1105) 1105
follow-up studies (1103) 1103
clinical trials (1102) 1102
tumors (1098) 1098
surgery (1038) 1038
antineoplastic combined chemotherapy protocols - adverse effects (1035) 1035
lung neoplasms - drug therapy (1026) 1026
antineoplastic agents (1007) 1007
hematology, oncology and palliative medicine (993) 993
antimitotic agents (968) 968
fluorescein angiography (934) 934
patients (931) 931
health aspects (903) 903
neoplasm metastasis (892) 892
cetuximab (884) 884
neoplasm staging (883) 883
prospective studies (870) 870
combination (869) 869
phase-ii trial (864) 864
visual acuity - physiology (847) 847
fluorouracil (834) 834
combined modality therapy (829) 829
bevacizumab - administration & dosage (825) 825
1st-line treatment (813) 813
phase-iii trial (807) 807
paclitaxel (803) 803
fluorouracil - administration & dosage (799) 799
eye diseases (798) 798
carcinoma, non-small-cell lung - drug therapy (786) 786
abridged index medicus (783) 783
expression (778) 778
cancer therapies (776) 776
oxaliplatin (774) 774
camptothecin - analogs & derivatives (770) 770
brain neoplasms - drug therapy (764) 764
mice (762) 762
survival rate (761) 761
antibodies, monoclonal - adverse effects (759) 759
neovascularization, pathologic - drug therapy (752) 752
article (738) 738
irinotecan (731) 731
neovascularization (725) 725
leucovorin (721) 721
metastatic colorectal-cancer (701) 701
vascular endothelial growth factor a - metabolism (693) 693
breast neoplasms - drug therapy (689) 689
visual acuity (689) 689
intravitreal bevacizumab (685) 685
antibodies, monoclonal, humanized - adverse effects (677) 677
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (13300) 13300
Japanese (269) 269
French (182) 182
German (138) 138
Spanish (52) 52
Chinese (46) 46
Hungarian (28) 28
Czech (16) 16
Italian (14) 14
Portuguese (14) 14
Korean (11) 11
Polish (11) 11
Romanian (11) 11
Russian (10) 10
Dutch (7) 7
Finnish (5) 5
Hebrew (2) 2
Slovak (2) 2
Swedish (2) 2
Icelandic (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, pp. CD007419 - CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti-vascular endothelial growth factor... 
CLINICAL-TRIAL | RANIBIZUMAB PLUS PROMPT | RANDOMIZED CONTROLLED-TRIAL | Receptors, Vascular Endothelial Growth Factor [therapeutic use] | DEFERRED LASER | MEDICINE, GENERAL & INTERNAL | PEGAPTANIB SODIUM | Bevacizumab [adverse effects; therapeutic use] | Laser Coagulation [methods] | Aptamers, Nucleotide [adverse effects; therapeutic use] | Network Meta-Analysis | QUALITY-OF-LIFE | Macular Edema [drug therapy; etiology; surgery] | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | Visual Acuity [drug effects; physiology] | COST-EFFECTIVENESS | Angiogenesis Inhibitors [adverse effects; therapeutic use] | LASER PHOTOCOAGULATION | Randomized Controlled Trials as Topic | Ranibizumab [adverse effects; therapeutic use] | Recombinant Fusion Proteins [adverse effects; therapeutic use] | Quality of Life | INTRAVITREAL BEVACIZUMAB | Diabetic Retinopathy [complications] | Triamcinolone [adverse effects; therapeutic use] | VEGF TRAP-EYE | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy | Index Medicus
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 8, pp. 760 - 767
Purpose This international phase III trial (Investigating Torisel As Second-Line Therapy [INTORSECT]) compared the efficacy of temsirolimus (mammalian target... 
SURVIVAL | INTERFERON-ALPHA | EVEROLIMUS | ONCOLOGY | BEVACIZUMAB | DOUBLE-BLIND | AGENTS | Niacinamide - analogs & derivatives | TOR Serine-Threonine Kinases - metabolism | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | TOR Serine-Threonine Kinases - antagonists & inhibitors | Young Adult | Receptors, Vascular Endothelial Growth Factor - metabolism | Time Factors | Phenylurea Compounds - adverse effects | Treatment Failure | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Carcinoma, Renal Cell - enzymology | Female | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Angiogenesis Inhibitors - adverse effects | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Kaplan-Meier Estimate | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Kidney Neoplasms - mortality | Disease Progression | Carcinoma, Renal Cell - mortality | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Renal Cell - secondary | Kidney Neoplasms - enzymology | Indoles - therapeutic use | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Index Medicus | ORIGINAL REPORTS
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9807, pp. 1931 - 1939
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 1, pp. 38 - 47
Summary Background Neoadjuvant chemotherapy for unresectable colorectal liver metastases can downsize tumours for curative resection. We assessed the... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | 1ST-LINE TREATMENT | LEUCOVORIN | PLUS IRINOTECAN | ONCOLOGY | BEVACIZUMAB | OXALIPLATIN | FLUOROURACIL | HEPATIC RESECTION | CANCER | CARCINOMA | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Tomography, Spiral Computed | Liver Neoplasms - chemistry | Hepatectomy | Antibodies, Monoclonal, Humanized | Fluorouracil - therapeutic use | Austria | Leucovorin - adverse effects | Fluorouracil - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Female | Leucovorin - therapeutic use | Neoadjuvant Therapy | Retrospective Studies | Chemotherapy, Adjuvant | Cetuximab | Liver Neoplasms - secondary | Odds Ratio | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Camptothecin - therapeutic use | Liver Neoplasms - genetics | Risk Assessment | Liver Neoplasms - drug therapy | Linear Models | Liver Neoplasms - surgery | Proto-Oncogene Proteins - genetics | Treatment Outcome | Receptor, Epidermal Growth Factor - analysis | Magnetic Resonance Imaging | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Aged | Mutation | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Germany | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 10, pp. 1065 - 1075
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 07/2014, Volume 12, Issue 7, pp. 1028 - 1059
The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance,... 
PHASE-III TRIAL | GROWTH-FACTOR RECEPTOR | UNRESECTABLE LIVER METASTASES | BEVACIZUMAB-CONTAINING ARMS | ONCOLOGY | HIGH-DOSE LEUCOVORIN | POSTPROGRESSION SURVIVAL-TIME | 1ST-LINE COMBINATION CHEMOTHERAPY | KRAS WILD-TYPE | CAPECITABINE PLUS OXALIPLATIN | METASTATIC COLORECTAL-CANCER | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Colonic Neoplasms - drug therapy | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Bevacizumab | Colonic Neoplasms - surgery | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Angiogenesis Inhibitors - therapeutic use | Deoxycytidine - adverse effects | Leucovorin - therapeutic use | Cetuximab | Liver Neoplasms - secondary | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Camptothecin - therapeutic use | Fluorouracil - analogs & derivatives | Membrane Proteins - genetics | Liver Neoplasms - drug therapy | Liver Neoplasms - surgery | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease Progression | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Colonic Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 13, pp. 1302 - 1308
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1355 - 1369
Journal Article